Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00222053 | IFM 99-02 Thalidomide in Myeloma | completed | Phase 3 | 800 | University Hospital, ToulouseOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00179647 | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 1,913 | Celgene CorporationINDUSTRY | 2 | Mar 16, 2010 | clinicaltrials |
| NCT01085058 |
| Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) |
| completed |
| Phase 2 / Phase 3 |
| 169 |
| WiSP Wissenschaftlicher Service Pharma GmbHOTHER |
| 0 |
| Mar 11, 2010 |
| clinicaltrials |
| NCT00304590 | Study of XL999 in Patients With Multiple Myeloma | terminated | Phase 2 | 4 | Symphony Evolution, Inc.INDUSTRY | 1 | Feb 22, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 | clinicaltrials |
| NCT01066429 | DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma | unknown | Phase 2 | 30 | Hospital Universitario Principe de AsturiasOTHER | 1 | Feb 12, 2010 | clinicaltrials |
| NCT00124813 | Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma | unknown | Phase 2 | 80 | University Hospital, BonnOTHER | 1 | Feb 2, 2010 | clinicaltrials |
| NCT00251394 | Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 29, 2010 | clinicaltrials |
| NCT00147953 | Study to Evaluate the Efficacy of Rituximab in Combination With Low-dose Radiotherapy in Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 2 | 30 | University of CologneOTHER | 1 | Jan 27, 2010 | clinicaltrials |
| NCT00301288 | A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). | completed | — | 152 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00301301 | A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) | completed | — | 39 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00301314 | A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Hodgkin Lymphoma (HL). | completed | — | — | Royal Marsden NHS Foundation TrustOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00571168 | Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy(EmNa) | unknown | Phase 3 | 362 | Heidelberg UniversityOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00276003 | INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma. | completed | Phase 2 | 22 | University of New MexicoOTHER | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00229203 | A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma | completed | Phase 2 | 51 | PharmaMarINDUSTRY | 1 | Dec 24, 2009 | clinicaltrials |
| NCT00161239 | LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma | terminated | N/A | 64 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Dec 11, 2009 | clinicaltrials |
| NCT00466258 | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)(LINFOTARGAM) | completed | Phase 4 | 50 | PETHEMA FoundationOTHER | 1 | Nov 25, 2009 | clinicaltrials |
| NCT01018758 | Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy(NHLPal) | completed | Phase 2 | 86 | Gruppo Italiano Studio LinfomiOTHER | 1 | Nov 25, 2009 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00195533 | Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | completed | — | 801 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 16, 2009 | clinicaltrials |
| NCT00608452 | Prevalence+Significance of Paraneoplastic Autoantibodies in Many Cancers | completed | — | 121 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 13, 2009 | clinicaltrials |
| NCT01008735 | Gonadal Toxicity in Women With Hodgkin Lymphoma(FertHD) | unknown | — | 150 | Gruppo Italiano Studio LinfomiOTHER | 1 | Nov 13, 2009 | clinicaltrials |
| NCT00136474 | Amifostine for Head and Neck Irradiation in Lymphoma | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00165269 | Mantle Irradiation for Hodgkin's Disease | completed | Phase 2 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2009 | clinicaltrials |
| NCT00418535 | Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma | completed | Phase 2 | — | Samsung Medical CenterOTHER | 1 | Oct 21, 2009 | clinicaltrials |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 4 | 168 | BiogenINDUSTRY | 11 | Oct 20, 2009 | clinicaltrials |
| NCT00374699 | Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | Samsung Medical CenterOTHER | 1 | Oct 14, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00041730 | Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma | unknown | Phase 2 | 90 | FavrilleINDUSTRY | 1 | Sep 30, 2009 | clinicaltrials |
| NCT00471367 | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 | terminated | Phase 1 | 44 | AstraZenecaINDUSTRY | 1 | Sep 24, 2009 | clinicaltrials |
| NCT00051116 | A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma | completed | Phase 2 | 100 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00354822 | Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.(Z0105) | terminated | Phase 2 | 25 | A.O. Ospedale Papa Giovanni XXIIIOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00391157 | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma | completed | Phase 2 | 40 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00797810 | Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults | unknown | Phase 4 | 25 | University of BolognaOTHER | 1 | Sep 15, 2009 | clinicaltrials |
| NCT00970385 | Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma(LTP) | completed | Phase 3 | 95 | University Hospital, GrenobleOTHER | 1 | Sep 9, 2009 | clinicaltrials |
| NCT00147875 | Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Elderly Patients With Advanced Stages Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 60 | University of CologneOTHER | 1 | Sep 7, 2009 | clinicaltrials |
| NCT00474188 | A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | terminated | Phase 2 | 26 | Celgene CorporationINDUSTRY | 3 | Sep 2, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00946374 | Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma(HD-MCL2003) | unknown | Phase 2 | 20 | Heidelberg UniversityOTHER | 1 | Jul 27, 2009 | clinicaltrials |
| NCT00210327 | VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy | completed | Phase 2 | 33 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jul 22, 2009 | clinicaltrials |
| NCT00117897 | Treatment for Subjects With Non-Hodgkin's Lymphoma | completed | Phase 2 | — | AmgenINDUSTRY | 0 | Jul 20, 2009 | clinicaltrials |
| NCT00436059 | The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) | completed | Phase 2 | 20 | Vejle HospitalOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00932217 | Study on the Incidence of Febrile Episodes During Stem Cells Collection After Chemotherapy in Patients With Multiple Myeloma | unknown | Phase 3 | 180 | University of PisaOTHER | 0 | Jul 3, 2009 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2010source: clinicaltrials